FASLODEX
Total Payments
$16.1M
Transactions
8,660
Doctors
3,002
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $263,263 | 12 | 8 |
| 2023 | $267,132 | 58 | 35 |
| 2022 | $243,213 | 89 | 47 |
| 2021 | $451,719 | 158 | 74 |
| 2020 | $841,000 | 133 | 53 |
| 2019 | $649,951 | 390 | 202 |
| 2018 | $6.3M | 2,884 | 1,397 |
| 2017 | $7.1M | 4,936 | 2,296 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15.5M | 257 | 96.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $225,125 | 97 | 1.4% |
| Food and Beverage | $146,989 | 8,020 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $108,500 | 97 | 0.7% |
| Consulting Fee | $88,099 | 35 | 0.5% |
| Travel and Lodging | $34,499 | 89 | 0.2% |
| Education | $4,681 | 65 | 0.0% |
Payments by Type
Research
$15.5M
257 transactions
General
$607,894
8,403 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ALTernate approaches for clinical stage II and III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) Study. | AstraZeneca Pharmaceuticals LP | $11.3M | 0 |
| A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women with Advanced Low Grade Serous Carcinoma | AstraZeneca Pharmaceuticals LP | $718,540 | 0 |
| Phase III Randomized Trial of Anastrozole versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metatstatic Breast Cancer | AstraZeneca Pharmaceuticals LP | $610,407 | 0 |
| A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, ER positive, HER2 negative breast cancer (DARE) | AstraZeneca Pharmaceuticals LP | $591,410 | 0 |
| A single arm, open label phase I/II trial of Olaparib plus Palbociclib and Fulvestrant in patients with BRCA mutation-associated ER-positive metastatic breast cancer | AstraZeneca Pharmaceuticals LP | $496,959 | 0 |
| Phase II Trial of Fulvestrant versus Tamoxifen in ER MBC Patients with ESR1 Mutations | AstraZeneca Pharmaceuticals LP | $466,534 | 0 |
| A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer | AstraZeneca Pharmaceuticals LP | $389,069 | 0 |
| SWOG S1222 Collaborative Post AI Study | AstraZeneca Pharmaceuticals LP | $269,328 | 0 |
| A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy (FALCON) | AstraZeneca UK Limited | $170,679 | 0 |
| A Phase II Multicenter Study to Evaluate the Efficacy and Safety of 500 mg of fulvestrant Faslodex as a First Line Hormonal Treatment in Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer | AstraZeneca Pharmaceuticals LP | $143,572 | 0 |
| RWE- Current Treatment Patterns and Outcomes in Metastatic Breast Cancer Patients Treated with Fulvestrant | AstraZeneca Pharmaceuticals LP | $123,960 | 0 |
| GOG 0188 Ph II Study of Faslodex in Recurrent Metastatic Endometrial Cancer | AstraZeneca Pharmaceuticals LP | $87,257 | 0 |
| A Randomized, Open-label Phase II Clinical Trial of Combination Gefitinib Iressa and Fulvestrant Faslodex versus Gefitinib Iressa Alone in Advanced Non-Small Cell Lung Cancer Patients whose Tumors Express Epidermal Growth Factor and Estrogen Receptors | AstraZeneca Pharmaceuticals LP | $57,028 | 0 |
| \";A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy (FALCON)\"; | AstraZeneca UK Limited | $55,765 | 0 |
| Comparison in the Change of Proliferation Index Between Fulvestrant and Tamoxifen in Cyclin D1 Estrogen Receptor Breast Cancer | AstraZeneca Pharmaceuticals LP | $29,360 | 0 |
| An Open-label, Non Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of FASLODEX (fulvestrant) in girls with Progressive Precocious Puberty associated with McCune-Albright Syndrome | AstraZeneca Pharmaceuticals LP | $1,500 | 0 |
Top Doctors Receiving Payments for FASLODEX
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Iowa City, IA | $15.6M | 358 |
| , M.D., PHD | Hematology & Oncology | Torrance, CA | $47,911 | 54 |
| Claudine Isaacs | Hematology & Oncology | Baltimore, MD | $44,879 | 33 |
| , M.D | Hematology & Oncology | Sacramento, CA | $36,911 | 27 |
| , MD | Hematology & Oncology | Chicago, IL | $28,593 | 28 |
| , M.D | Hematology & Oncology | Portland, OR | $25,927 | 28 |
| , MD | Medical Oncology | Chandler, AZ | $21,061 | 30 |
| , MD | Medical Oncology | Saint Louis, MO | $19,104 | 16 |
| , M.D | Internal Medicine | Henderson, NV | $16,354 | 16 |
| , MD | Hematology & Oncology | Cincinnati, OH | $10,401 | 8 |
| Andrea Dickey | Medical Oncology | New Haven, CT | $10,201 | 7 |
| , M.D | Medical Oncology | Chicago, IL | $8,438 | 4 |
| , M.D | Medical Oncology | Fort Myers, FL | $8,346 | 9 |
| , M.D | Medical Oncology | Germantown, TN | $8,114 | 13 |
| , MD | Hematology | Germantown, TN | $7,332 | 2 |
| , MD | Hematology & Oncology | Tampa, FL | $6,140 | 3 |
| , MD | Hematology | Lebanon, NH | $5,398 | 3 |
| , MD | Medical Oncology | Seattle, WA | $4,565 | 1 |
| , MD PHD | Medical Oncology | Houston, TX | $3,083 | 2 |
| , MD | Medical Oncology | Atlanta, GA | $2,825 | 2 |
| , MD | Medical Oncology | Saint Louis, MO | $2,700 | 1 |
| , M.D | Hematology & Oncology | Williamsville, NY | $2,530 | 6 |
| , MD | Hematology & Oncology | Cookeville, TN | $2,386 | 3 |
| , M.D | Hematology & Oncology | Clinton, MD | $2,379 | 3 |
| , MD | Hematology & Oncology | Grand Rapids, MI | $2,376 | 3 |
Ad
Manufacturing Companies
- AstraZeneca Pharmaceuticals LP $15.9M
- AstraZeneca UK Limited $226,842
Product Information
- Type Drug
- Total Payments $16.1M
- Total Doctors 3,002
- Transactions 8,660
About FASLODEX
FASLODEX is a drug associated with $16.1M in payments to 3,002 healthcare providers, recorded across 8,660 transactions in the CMS Open Payments database. The primary manufacturer is AstraZeneca Pharmaceuticals LP.
Payment data is available from 2017 to 2024. In 2024, $263,263 was paid across 12 transactions to 8 doctors.
The most common payment nature for FASLODEX is "Unspecified" ($15.5M, 96.2% of total).
FASLODEX is associated with 16 research studies, including "ALTernate approaches for clinical stage II and III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) Study." ($11.3M).